Analysts Set Masimo Co. (NASDAQ:MASI) PT at $194.80

Masimo Co. (NASDAQ:MASI) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $194.80.

Several analysts have recently weighed in on MASI shares. Wells Fargo & Company raised their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Raymond James lifted their price target on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Piper Sandler increased their price objective on Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Thursday.

Insider Activity

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company’s stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. The trade was a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Masimo

Several institutional investors and hedge funds have recently modified their holdings of MASI. FMR LLC boosted its position in shares of Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after purchasing an additional 1,340,836 shares in the last quarter. Capital Research Global Investors lifted its position in Masimo by 80.5% during the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock valued at $405,807,000 after buying an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock valued at $286,823,000 after buying an additional 943,001 shares in the last quarter. Alliancebernstein L.P. grew its position in shares of Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after buying an additional 878,587 shares during the period. Finally, Corient Private Wealth LLC increased its stake in shares of Masimo by 8,847.1% in the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock worth $57,472,000 after acquiring an additional 343,797 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Price Performance

Shares of NASDAQ MASI opened at $153.90 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The stock has a market cap of $8.32 billion, a PE ratio of 106.14 and a beta of 1.28. The stock has a fifty day moving average of $170.60 and a 200-day moving average of $164.48.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $600.70 million for the quarter, compared to analysts’ expectations of $593.35 million. Equities research analysts anticipate that Masimo will post 4.1 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.